excit
time
field
microbiolog
expans
rapid
diagnost
test
pathogen
test
previous
perform
tradit
laboratori
method
bacteri
fungal
viral
cultur
ova
parasit
p
examin
test
could
slow
time
result
test
lack
sensit
test
central
laboratori
newer
advanc
pathogen
detect
assay
provid
rapid
result
greater
sensit
specif
mani
assay
move
central
laboratori
patient
pointofcar
test
review
author
chose
highlight
current
avail
us
food
drug
administr
fda
clear
molecular
assay
variou
infecti
syndrom
relev
pediatr
popul
although
outcom
studi
area
spars
rapid
result
may
result
decreas
time
optim
antimicrobi
treatment
improv
patient
outcom
disclosur
statement
e
mcelvania
consult
luminex
corpor
md
gonzalez
disclosur
keyword
rapid
diagnost
assay
group
streptococcu
influenza
rsv
syndrom
multiplex
panel
gastrointestin
panel
respiratori
panel
mening
enceph
panel
compar
tradit
rapid
antigen
test
new
diagnost
assay
group
streptococcu
influenza
respiratori
syncyti
viru
combin
rapid
turnaround
time
high
sensit
specif
surg
avail
multiplex
syndrom
panel
test
broad
rang
pathogen
associ
singl
clinic
present
molecular
infecti
diseas
test
previous
perform
microbiolog
laboratori
develop
easytous
platform
avail
point
care
group
streptococcu
ga
streptococcu
pyogen
common
bacteri
caus
pharyng
infrequ
result
seriou
condit
bacteremia
poststreptococc
glomerulonephr
rheumat
fever
strep
throat
common
children
year
age
complic
fact
approxim
children
group
asymptomat
carrier
ga
throat
cultur
gold
standard
diagnosi
ga
pharyng
due
turnaround
time
rapid
antigen
test
standard
practic
emerg
depart
ed
outpati
clinic
mani
year
rapid
antigen
assay
low
sensit
compar
cultur
throat
swab
test
neg
ga
rapid
antigen
assay
must
cultur
collect
children
less
year
age
rapid
antigen
test
combin
reflex
throat
cultur
bring
sensit
ga
detect
accept
level
greater
increas
sensit
ga
detect
secondgener
antigen
assay
recent
develop
assay
use
read
devic
interpret
assay
rather
nake
eye
increas
sensit
antigen
detect
reduc
subject
natur
read
low
posit
test
result
studi
pediatr
patient
pharyng
sofia
strep
fid
quidel
corp
san
diego
ca
usa
sensit
specif
detect
ga
compar
cultur
illumigen
group
streptococcu
assay
meridian
bioscienc
inc
cincinnati
oh
usa
use
isotherm
amplif
detect
ga
found
sensit
specif
compar
cultur
studi
throat
swab
collect
primarili
pediatr
patient
patient
year
age
second
studi
pediatr
patient
report
illumigen
assay
sensit
specif
comparison
tradit
ga
rapid
antigen
test
also
run
specimen
studi
sensit
respect
specif
respect
simplexa
group
strep
direct
assay
diasorin
molecular
llc
cypress
ca
usa
found
sensit
specif
compar
cultur
studi
specimen
across
pediatr
test
site
molecular
test
also
develop
allow
rapid
pointofcar
detect
ga
assay
highli
sensit
specif
may
requir
reflex
cultur
test
neg
mani
test
also
clinic
laboratori
improv
amend
clia
waiv
allow
molecular
test
perform
nonlaboratori
personnel
physician
nurs
outpati
ed
set
coba
liat
strep
assay
roch
diagnost
indianapoli
usa
waiv
polymeras
chain
reaction
pcr
base
assay
found
sensit
specif
ga
detect
compar
inhous
develop
molecular
assay
use
throat
swab
adult
children
anoth
pointofcar
molecular
test
aler
strep
aler
inc
waltham
usa
studi
conduct
across
us
medic
center
primarili
pediatr
specimen
test
nonlaboratori
personnel
found
aler
strep
assay
sensit
specif
compar
bacteri
cultur
past
year
explos
field
ga
assay
new
assay
rapid
increas
sensit
tradit
rapid
antigen
test
mani
case
perform
point
care
molecular
test
sensit
cultur
clinician
must
cogniz
test
patient
sign
symptom
pharyng
prevent
detect
ga
colon
molecular
test
distinguish
live
dead
organ
molecular
test
use
determin
clearanc
ga
follow
treatment
test
ga
molecular
method
result
miss
opportun
detect
less
common
caus
bacteri
pharyng
lancefield
group
c
g
bhemolyt
streptococci
identifi
throat
cultur
effort
identifi
addit
bacteri
caus
pharyng
assay
simplexa
group
strep
assay
detect
lancefield
group
c
g
bhemolyt
streptococci
addit
ga
summari
fdaclear
rapid
secondgener
molecular
ga
assay
found
tabl
million
children
infect
year
influenza
respiratori
syncyti
viru
rsv
even
fall
ill
varieti
respiratori
virus
respiratori
viral
infect
span
clinic
spectrum
symptom
death
rare
case
children
age
especi
year
age
high
risk
complic
influenza
result
thousand
hospit
approxim
death
per
year
rsv
lead
caus
bronchiol
pneumonia
children
year
age
caus
hospit
children
year
tradit
viral
cultur
gold
standard
respiratori
viru
detect
long
turnaround
time
rapid
antigen
test
becam
mainstay
influenza
rsv
test
ed
outpati
set
like
rapid
antigen
test
ga
test
influenza
rsv
rapid
inexpens
lack
sensit
reason
center
diseas
control
prevent
cdc
discourag
use
rapid
antigen
test
influenza
rsv
promot
use
molecular
detect
virus
rapid
antigen
test
must
use
cdc
recommend
use
assay
preval
influenza
rsv
commun
greater
rais
posit
predict
valu
assay
even
preval
high
clinician
must
interpret
rapid
antigen
test
result
caution
neg
result
exclud
infect
symptomat
patient
like
ga
test
secondgener
rapid
antigen
assay
use
read
devic
develop
increas
sensit
influenza
rsv
detect
studi
pediatr
specimen
test
secondgener
influenza
platform
veritor
system
flu
b
bd
diagnost
spark
md
usa
sofia
influenza
b
fia
quidel
corp
san
diego
ca
usa
binaxnow
influenza
b
aler
scarborough
inc
scarborough
usa
found
test
agreement
time
influenza
time
influenza
b
respect
compar
realtim
pcr
assay
use
molecular
method
influenza
rsv
detect
drastic
increas
sensit
viral
detect
previou
method
includ
rapid
antigen
test
viral
cultur
increas
speed
detect
partial
due
remov
extern
extract
step
molecular
test
allow
test
platform
simplexa
excit
new
develop
field
influenza
rsv
detect
develop
rapid
pointofcar
molecular
test
assay
combin
quick
new
develop
rapid
diagnost
test
turnaround
time
rapid
antigen
test
high
sensit
specif
associ
molecular
test
sever
assay
clia
waiv
perform
point
care
nonlaboratorytrain
individu
although
molecular
assay
cost
tradit
rapid
antigen
assay
provid
accur
test
result
patient
seen
clinic
ed
allow
treatment
decis
made
patient
hous
studi
specimen
collect
children
found
aler
influenza
b
assay
sensit
specif
influenza
sensit
specif
influenza
b
compar
viral
cultur
realtim
revers
transcript
rt
pcr
use
discrep
analysi
studi
cliawaiv
pointofcar
molecular
assay
coba
liat
influenza
ab
roch
diagnost
indianapoli
usa
aler
influenza
b
aler
scarborough
inc
scarborough
usa
test
respiratori
specimen
pediatr
specimen
found
aler
sensit
influenza
sensit
influenza
b
specif
virus
coba
liat
sensit
specif
influenza
b
low
sensit
aler
thought
due
specimen
limit
detect
lod
assay
sinc
studi
assay
revis
address
issu
summari
fdaclear
rapid
secondgener
molecular
influenza
combin
influenza
rsv
assay
found
tabl
although
influenza
rsv
common
respiratori
pathogen
mani
respiratori
virus
caus
signific
diseas
especi
immunosuppress
patient
advent
syndrom
multiplex
assay
allow
rapid
identif
larg
number
respiratori
pathogen
bacteri
viral
respiratori
specimen
tabl
studi
respiratori
specimen
pediatr
patient
test
multiplex
respiratori
panel
filmarray
rp
genmark
dx
esensor
genmark
diagnost
inc
carlsbad
ca
usa
luminex
xtag
luminex
austin
tx
usa
luminex
xtag
rieux
durham
nc
usa
rvp
fast
overal
sensit
filmarray
rp
esensor
rvp
luminex
austin
tx
usa
xtag
rvp
fast
specif
greater
assay
note
assay
use
updat
sinc
time
studi
recent
first
cliawaiv
respiratori
panel
filmarray
respiratori
panel
ez
rieux
durham
nc
usa
come
market
allow
respiratori
panel
perform
outpati
set
inform
rapid
influenza
respiratori
panel
test
found
recent
clinic
laboratori
medicin
articl
peaper
landri
buller
rapid
influenza
test
valuabl
convenienceit
affect
patient
outcom
studi
influenza
test
pediatr
patient
present
ed
found
use
rapid
multiplex
pcr
costeffect
test
method
base
qualityadjust
lifeyear
compar
tradit
pcr
directfluoresc
antibodi
rapid
antigen
test
metaanalysi
greater
pediatr
patient
found
rapid
influenza
detect
ed
decreas
antibiot
usag
trend
statist
signific
studi
find
rapid
viral
test
avail
significantli
decreas
rate
chest
radiograph
perform
ed
anoth
pediatr
studi
roger
colleagu
found
implement
biofir
rp
reduc
antibiot
durat
test
result
obtain
less
hour
also
test
result
posit
respiratori
viru
inpati
length
stay
time
isol
decreas
compar
biofir
rp
use
tradit
test
array
gastrointestin
pathogen
includ
bacteria
virus
parasit
reli
rang
test
methodolog
decis
appropri
test
order
complic
lack
symptom
biomark
reliabl
differenti
pathogen
group
identif
bacteri
pathogen
reli
stool
cultur
take
day
result
reduc
sensit
fastidi
natur
pathogen
campylobact
shigella
effort
increas
sensit
campylobact
detect
stool
specimen
antigen
test
avail
rapid
campylobact
spp
test
unfortun
larg
multicent
studi
evalu
campylobact
antigen
assay
found
despit
rel
high
specif
posit
predict
valu
base
result
use
campylobact
antigen
assay
standalon
test
recommend
antigen
test
also
use
detect
viral
parasit
caus
gastroenter
includ
adenoviru
rotaviru
giardia
lamblia
cryptosporidium
antigen
test
offer
rapid
rel
sensit
method
viral
parasit
pathogen
detect
rel
viral
cultur
p
examin
rapid
antigen
test
parasit
requir
multipl
specimen
rule
infect
practic
p
examin
reader
refer
review
protozo
diagnost
addit
inform
detect
noroviru
alway
difficult
cultur
year
laboratorydevelop
molecular
test
method
noroviru
test
recent
first
fdaclear
molecular
assay
xpert
noroviru
cepheid
sunnyval
ca
usa
becam
avail
detect
noroviru
genogroup
gi
gii
stool
specimen
multicent
studi
approxim
fresh
frozen
stool
specimen
assay
demonstr
high
sensit
specif
noroviru
genogroup
much
overlap
symptom
bacteri
viral
caus
gastroenter
make
unabl
differenti
clinic
often
clinician
awar
bacteria
includ
institut
standard
stool
cultur
vari
among
laboratori
solv
problem
multiplex
syndrom
panel
avail
detect
numer
gastrointestin
pathogen
filmarray
gastrointestin
rieux
durham
nc
usa
xtag
gastrointestin
luminex
austin
tx
usa
panel
detect
bacteri
viral
parasit
target
wherea
verigen
enter
pathogen
panel
luminex
austin
tx
usa
detect
bacteri
viral
pathogen
progastro
ssc
holog
inc
marlborough
usa
detect
bacteri
pathogen
wherea
bdmax
enter
system
bd
franklin
lake
nj
usa
bacteri
panel
extend
bacteri
panel
parasit
panel
assay
target
summar
tabl
studi
assay
publish
assay
show
high
sensit
specif
respect
target
fact
multiplex
panel
result
increas
unexpect
detect
would
identifi
order
prefer
clinician
exampl
studi
stockmann
colleagu
note
patient
clostridium
difficil
test
filmarray
gastrointestin
pathogen
panel
identifi
altern
pathogen
patient
current
studi
directli
compar
multiplex
panel
huang
colleagu
evalu
perform
share
analyt
verigen
enter
filmarray
gastrointestin
xtag
gastrointestin
panel
found
filmarray
xtag
panel
perform
similarli
except
reduc
salmonella
detect
later
assay
rel
former
assay
verigen
enter
panel
demonstr
similar
specif
assay
reduc
sensit
detect
campylobact
salmonella
noroviru
rotaviru
anoth
studi
investig
evalu
filmarray
gastrointestin
xtag
gastrointestin
panel
found
similar
perform
test
share
analyt
except
xtag
panel
demonstr
lower
specif
noroviru
prospect
retrospect
specimen
final
studi
chhabra
colleagu
investig
specif
examin
analyt
perform
filmarray
gastrointestin
xtag
gastrointestin
panel
detect
gastrointestin
virus
investig
note
filmarray
gastrointestin
panel
demonstr
overal
better
analyt
perform
viral
detect
rel
xtag
panel
although
multiplex
gastrointestin
panel
offer
rapid
result
clinician
present
potenti
problem
public
health
surveil
effort
bacteri
pathogen
cultur
addit
lack
bacteri
isol
could
complic
treatment
without
antimicrobi
suscept
result
anoth
caveat
molecular
panel
test
multipl
pathogen
present
observ
specimen
multicent
studi
filmarray
xtag
gastrointestin
panel
clinic
signific
multipl
posit
target
current
unclear
caus
frustrat
clinician
unsur
target
target
detect
respons
patient
symptom
final
limit
inform
avail
repeat
multiplex
test
park
colleagu
retrospect
evalu
patient
initi
neg
filmarray
gastrointestin
result
found
remain
neg
upon
retest
within
week
convers
patient
initi
posit
result
remain
posit
target
within
week
continu
asymptomat
shed
observ
gastrointestin
pathogen
taken
togeth
result
show
molecular
test
appropri
test
cure
continu
detect
target
occur
indetermin
amount
time
regardless
patient
symptom
absolut
necessari
restrict
test
symptomat
individu
care
interpret
repeat
posit
result
sever
multiplex
syndrom
panel
contain
target
c
difficil
pediatr
patient
american
academi
pediatr
guidelin
clostridium
difficil
infect
cdi
diagnosi
discourag
test
less
year
age
due
high
percentag
children
age
group
asymptomat
colon
c
difficil
children
age
year
caus
virus
consid
test
c
difficil
reason
discuss
c
difficil
test
outsid
scope
articl
author
refer
reader
review
c
difficil
test
pediatr
tradit
rapid
diagnost
test
cerebrospin
fluid
csf
specimen
use
cell
count
protein
glucos
gram
stain
howev
test
limit
analyt
sensit
specif
differenti
infecti
versu
noninfecti
caus
differenti
bacteri
versu
viral
versu
fungal
pathogen
gold
standard
identif
bacteri
pathogen
csf
cultur
wherea
fungal
caus
identifi
cultur
antigen
test
eg
cyptococc
antigen
test
bacteri
fungal
cultur
take
day
grow
test
obtain
result
addit
treatment
antimicrobi
therapi
obtain
csf
reduc
microbi
viabil
leav
clinician
without
target
therapi
exist
bacteri
antigen
test
csf
specimen
provid
rapid
result
test
recommend
infecti
diseas
societi
america
viral
test
perform
new
develop
rapid
diagnost
test
use
molecularbas
method
surpass
viral
cultur
sensit
turnaround
time
molecular
test
csf
specimen
viral
pathogen
frequent
perform
use
laboratori
develop
test
ldt
use
variou
method
nucleic
acid
extract
purif
oligonucleotid
primer
set
detect
method
taken
togeth
creat
interlaboratori
variabl
test
perform
requir
clinician
awar
rel
perform
institut
assay
current
standalon
fdaclear
assay
detect
viral
pathogen
csf
specimen
cepheid
xpert
ev
enteroviru
cepheid
sunnyval
ca
usa
simplexa
hsv
direct
tabl
qualit
assay
perform
directli
csf
specimen
xpert
ev
diasorin
molecular
llc
cypress
ca
usa
detect
array
enteroviru
serotyp
parechovirus
overal
demonstr
high
sensit
specif
similarli
simplexa
hsv
direct
shown
high
sensit
specif
although
depend
compar
ldt
lod
may
slightli
higher
evalu
ldt
one
fdaclear
syndrom
multiplex
panel
filmarray
mening
enceph
panel
rieux
durham
nc
usa
tabl
detect
bacteri
n
viral
n
fungal
pathogen
n
csf
specimen
one
larg
prospect
studi
examin
csf
specimen
adult
children
use
filmarray
meningitisenceph
panel
found
posit
greater
neg
agreement
compar
method
although
note
addit
pathogen
detect
use
filmarray
meningitisenceph
panel
also
unconfirmedfals
posit
detect
streptococcu
pneumonia
n
frequent
unconfirmedfals
posit
target
investig
propos
could
oral
flora
contamin
test
necessit
need
adher
strict
molecular
test
procedur
pediatr
specif
studi
examin
filmarray
meningitisenceph
panel
strong
agreement
seen
convent
method
although
studi
herp
simplex
viru
hsv
detect
miss
filmarray
meningitisenceph
panel
like
near
lod
assay
detect
specimen
standardofcar
ldt
note
studi
found
panel
demonstr
reduc
sensit
cryptococcu
detect
rel
antigen
test
final
date
clinic
report
perform
assay
detect
rel
low
incid
pathogen
listeria
monocytogen
report
neisseria
meningitidi
detect
panel
molecular
test
bacteri
fungal
csf
pathogen
replac
tradit
cultur
cultur
provid
isol
antimicrobi
suscept
test
detect
pathogen
panel
care
interpret
result
csf
multiplex
panel
need
take
account
patient
clinic
pictur
fals
posit
result
occur
contamin
event
particular
posit
result
herp
virus
eg
cytomegaloviru
hsv
human
herpesviru
varicella
zoster
viru
could
repres
detect
latent
activ
replic
viru
k
kinga
frequent
colon
oropharynx
young
children
month
age
preval
increas
children
attend
daycar
children
colon
k
kinga
bacteria
transloc
bloodstream
caus
bacteremia
seed
distal
bodi
site
primarili
joint
bone
caus
infect
k
kinga
fastidi
bacterium
rare
grow
cultur
septic
joint
improv
sensit
pathogen
detect
excess
joint
fluid
inocul
blood
cultur
bottl
incub
increas
recoveri
k
kinga
although
fdaclear
molecular
assay
detect
k
kinga
test
offer
refer
laboratori
hospit
ldt
pcr
assay
use
clinic
pediatr
orthoped
practic
routin
test
k
kinga
patient
year
age
use
either
k
kingaespecif
pcr
assay
ribosom
dna
sequenc
directli
joint
specimen
inocul
joint
fluid
blood
cultur
bottl
molecular
detect
assay
markedli
improv
rate
k
kinga
detect
joint
specimen
compar
bacteri
cultur
alon
new
diagnost
assay
ga
influenza
rsv
press
boundari
maintain
rapid
turnaround
time
provid
increas
sensit
specif
pathogen
detect
molecular
test
longer
confin
wall
laboratori
reimagin
easytous
platform
use
nonlaboratori
personnel
point
care
addit
multiplex
syndrom
panel
allow
broad
test
pathogen
associ
singl
clinic
present
singl
assay
togeth
clinician
rapid
accur
pathogen
detect
children
may
result
decreas
time
optim
antimicrobi
treatment
improv
patient
outcom
